Articles

2019 VCRC/VF Fellow Joins UPMC as Vasculitis Center Director

Note: Sebastian Sattui, MD, MS, completed his Vasculitis Clinical Research Consortium-Vasculitis Foundation (VCRC-VF) fellowship at the end of June 2021. Dr. Sattui was at the Hospital for Special Surgery in New York City for four years and during the first two years, he focused on his general rheumatology training. The…...

Read more

Introducing Our 2020-2021 VCRC-VF Fellow: Alvise Berti, MD

Dr. Berti began his work in vasculitis while he was a medical student at Vita-Salute San Raffaele University in Milan, Italy. At the time, Dr. Berti recognized that vasculitis was not very well understood, and being both curious and motivated to further explore this group of diseases, he realized that…...

Read more

ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis

October 8. 2021 ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis ChemoCentryx announced today that the U.S. Food and Drug Administration (FDA) has approved TAVNEOS (avacopan) as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), and specifically for granulomatosis with polyangiitis…...

Read more

New Handout Provides Family Planning and Birth Control Information

We are excited to introduce the release of our new handout designed for our patients who have questions about family planning and birth control. The two-page handout is intended to offer a reference for patients to use when talking with their health care providers about these important issues. The handout…...

Read more

ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis

07/06/21 ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis SAN CARLOS, Calif., July 06, 2021 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that, following consultations with the U.S. Food and Drug Administration (FDA),…...

Read more